ClinicalTrials.gg
Sign In

Drug

MK-0616 clinical trials

Also written MK-0616 and Enlicitide Decanoate.

studies test it
15
open now
2
in phase 3
6
first study started
2022

Keep track of what changes. Save the MK-0616 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

Enlicitide
3

Development codes

MK-0616
14

Other names

Enlicitide Decanoate
13

Studies by the year they started

15 studies that test it; most in 2023 (6)

Studies that test MK-0616, by start year
YearStudies
20222
20236
20245
20251
20261

By phase

A phase 1/2 study counts in both.

Phase 1
8
Phase 2
2
Phase 3
6

What it is tested for

Each study’s main condition, where its own words name it.

Hypercholesterolemia
5
Arteriosclerosis
1
Hyperlipoproteinemia Type II
1

Who runs them

Industry 15 · Other 0

Merck Sharp & Dohme LLC (15)

Often tested with

Tested in the same studies.

Alendronate (1) · Semaglutide (1) · Atorvastatin (1) · Thyroxine (1)

Studies

Open first, then newest update. How each study uses MK-0616 is read from its arms, and is right about nine times in ten.

Testing it · 15

Given in every arm · 1 — MK-0616 is usual care beside what is tested

Codes

What other systems call MK-0616 · ClinicalTrials.gg INT002031

  • MeSH (NLM) C000728674MK-0616One source ClinicalTrials.gov

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.